Since Beijing and Washington imposed tariffs on each other's goods this month, Western media have been closely monitoring whether the trade war will ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Karen Andersen, equity strategist at Morningstar, has issued an analysis of US pharma major Eli Lilly’s latest financial results, which were published yesterday.

Value often matches growth on a monthly basis, but growth’s wins are bigger. Value stocks beat growth stocks in January after ...